S R Smith1, B R Deshpande2, J E Collins3, J N Katz4, E Losina5. 1. Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: ssmith94@partners.org. 2. Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: bdeshpande@partners.org. 3. Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: jcollins13@partners.org. 4. Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA; Departments of Epidemiology and Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA. Electronic address: jnkatz@partners.org. 5. Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. Electronic address: elosina@partners.org.
Abstract
OBJECTIVE: Summarize the comparative effectiveness of oral non-steroidal anti-inflammatory drugs (NSAIDs) and opioids in reducing knee osteoarthritis (OA) pain. METHODS: Two reviewers independently screened reports of randomized controlled trials (RCTs), published in English between 1982 and 2015, evaluating oral NSAIDs or opioids for knee OA. Included studies were at least 8 weeks duration, conducted in Western Europe, the Americas, New Zealand, or Australia, and reported baseline and follow-up pain using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale (0-100, 100-worst). Effectiveness was evaluated as reduction in pain, accounting for study dropout and heterogeneity. RESULTS: Twenty-seven treatment arms (nine celecoxib, four non-selective NSAIDs [diclofenac, naproxen, piroxicam], eleven less potent opioids [tramadol], and three potent opioids [hydromorphone, oxycodone]) from 17 studies were included. NSAID and opioid studies reported similar baseline demographics and efficacy withdrawal rates; NSAID studies reported lower baseline pain and toxicity withdrawal rates. Accounting for efficacy-related withdrawals, all drug classes were associated with similar pain reductions (NSAIDs: -18; less potent opioids: -18; potent opioids: -19). Meta-regression did not reveal differential effectiveness by drug class but found that study cohorts with a higher proportion of male subjects and worse mean baseline pain had greater pain reduction. Similarly, results of the network meta-analysis did not find a significant difference in WOMAC Pain reduction for the three analgesic classes. CONCLUSION: NSAIDs and opioids offer similar pain relief in OA patients. These data could help clinicians and patients discuss likely benefits of alternative analgesics.
OBJECTIVE: Summarize the comparative effectiveness of oral non-steroidal anti-inflammatory drugs (NSAIDs) and opioids in reducing knee osteoarthritis (OA) pain. METHODS: Two reviewers independently screened reports of randomized controlled trials (RCTs), published in English between 1982 and 2015, evaluating oral NSAIDs or opioids for knee OA. Included studies were at least 8 weeks duration, conducted in Western Europe, the Americas, New Zealand, or Australia, and reported baseline and follow-up pain using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale (0-100, 100-worst). Effectiveness was evaluated as reduction in pain, accounting for study dropout and heterogeneity. RESULTS: Twenty-seven treatment arms (nine celecoxib, four non-selective NSAIDs [diclofenac, naproxen, piroxicam], eleven less potent opioids [tramadol], and three potent opioids [hydromorphone, oxycodone]) from 17 studies were included. NSAID and opioid studies reported similar baseline demographics and efficacy withdrawal rates; NSAID studies reported lower baseline pain and toxicity withdrawal rates. Accounting for efficacy-related withdrawals, all drug classes were associated with similar pain reductions (NSAIDs: -18; less potent opioids: -18; potent opioids: -19). Meta-regression did not reveal differential effectiveness by drug class but found that study cohorts with a higher proportion of male subjects and worse mean baseline pain had greater pain reduction. Similarly, results of the network meta-analysis did not find a significant difference in WOMAC Pain reduction for the three analgesic classes. CONCLUSION: NSAIDs and opioids offer similar pain relief in OA patients. These data could help clinicians and patients discuss likely benefits of alternative analgesics.
Authors: Andra Morrison; Julie Polisena; Don Husereau; Kristen Moulton; Michelle Clark; Michelle Fiander; Monika Mierzwinski-Urban; Tammy Clifford; Brian Hutton; Danielle Rabb Journal: Int J Technol Assess Health Care Date: 2012-04 Impact factor: 2.188
Authors: David S Jevsevar; Gregory Alexander Brown; Dina L Jones; Elizabeth G Matzkin; Paul A Manner; Pekka Mooar; John T Schousboe; Steven Stovitz; James O Sanders; Kevin J Bozic; Michael J Goldberg; William Robert Martin; Deborah S Cummins; Patrick Donnelly; Anne Woznica; Leeaht Gross Journal: J Bone Joint Surg Am Date: 2013-10-16 Impact factor: 5.284
Authors: C O Bingham; A I Sebba; B R Rubin; G E Ruoff; J Kremer; S Bird; S S Smugar; B J Fitzgerald; K O'Brien; A M Tershakovec Journal: Rheumatology (Oxford) Date: 2006-08-27 Impact factor: 7.580
Authors: Byron P DeLemos; Jim Xiang; Carmela Benson; Theophilus J Gana; Maria Luz G Pascual; R Rosanna; B Fleming Journal: Am J Ther Date: 2011-05 Impact factor: 2.688
Authors: Philip G Conaghan; John Dickson; Wolfgang Bolten; Gregor Cevc; Matthias Rother Journal: Rheumatology (Oxford) Date: 2013-03-28 Impact factor: 7.580
Authors: Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang Journal: Blood Adv Date: 2020-06-23
Authors: Elena Losina; Karen C Smith; A David Paltiel; Jamie E Collins; Lisa G Suter; David J Hunter; Jeffrey N Katz; Stephen P Messier Journal: Arthritis Care Res (Hoboken) Date: 2019-07 Impact factor: 4.794
Authors: K Blum; W Jacobs; E J Modestino; N DiNubile; D Baron; T McLaughlin; D Siwicki; I Elman; M Moran; E R Braverman; P K Thanos; R D Badgaiyan Journal: SEJ Surg Pain Date: 2018-10-04
Authors: S C Kim; N Choudhry; J M Franklin; K Bykov; M Eikermann; J Lii; M A Fischer; B T Bateman Journal: Osteoarthritis Cartilage Date: 2017-04-19 Impact factor: 6.576
Authors: E Losina; I M Usiskin; S R Smith; J K Sullivan; K C Smith; D J Hunter; S P Messier; A D Paltiel; J N Katz Journal: Osteoarthritis Cartilage Date: 2018-03-02 Impact factor: 6.576
Authors: Savannah R Smith; Jeffrey N Katz; Jamie E Collins; Daniel H Solomon; Joanne M Jordan; Lisa G Suter; Edward H Yelin; A David Paltiel; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2016-12-31 Impact factor: 4.794